To investigate the efficacy and safety of lenalidomide and dexamethasone for elderly or frail patients with relapsed/refractory multiple myeloma
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000008576
- Lead Sponsor
- Iwate Myeloma treatment Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of hypersensitivity to lenalidomide. 2. Non-secretory MM and plasma cell leukemia. 3. Patients HIV-positive, HBsAg-positive, HCV-positive. 4. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled hypertension, and uncontrolled infection. 5. Patients with psychiatric disorders. 6. Pregnant women, pre-menopausal women and lactating women. 7. Patients with a history of active malignancy. 8. Those who are considered as inappropriate register by attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method 1. Overall response rate 2. Incidents of adverse events 3. Discontinuation rate of treatment